Shenkute Demissew, Legese Melese Hailu, Yitayew Berhanu, Mitiku Asaye, Engidaye Getabalew, Gebremichael Saba, Asrat Daniel, Woldeamanuel Yimtubezinash
Department of Medical Laboratory Science, College of Health Sciences, Debre Berhan University, Debre Berhan, Ethiopia.
Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Infect Drug Resist. 2022 May 9;15:2445-2458. doi: 10.2147/IDR.S356807. eCollection 2022.
Gastrointestinal colonization rate of extended-spectrum beta-lactamase-producing (ESBL-PE) is the major risk factor for infection and dissemination of resistance clones in healthcare facilities. This study aimed to investigate the magnitude of the fecal carriage of ESBL-PE and associated factors among hospitalized patients at Debre Berhan Comprehensive Specialized Hospital, North Shoa, Amhara Regional State, Ethiopia.
A hospital-based cross-sectional study was conducted among 383 hospitalized patients from November 2020 to March 2021. Stool sample or rectal swab was aseptically collected and cultured on different culture media for isolation of . Identification was done by conventional biochemical tests. Screening of extended-spectrum beta-lactamase (ESBL) production was done by using cefotaxime and ceftazidime and confirmed by the combination disk method. Data analysis was performed by Statistical Package for Social Sciences software version 25 and a P-value ≤0.05 was considered as statistically significant.
From the total of 383 hospitalized patients, a total of 347 were isolated. The overall gastrointestinal colonization rate of ESBL-PE was 47.3% (164/347). The predominant ESBL-PE were 54.9% (90/164) and 33.5% (55/164). The overall multi-drug resistance rate (MDR) was 87.8% (305/347). The highest resistance was observed to ampicillin (98.3%), followed by gentamicin (80.7%), and tetracycline (73.3%), respectively. ESBL-PE were highly susceptible to meropenem (90.2%) and imipenem (89.0%). History of antibiotic use in the past 3 months (p<0.001), admission in the neonatal intensive care unit (p=0.023), and presence of chronic disease (p<0.001) were independently associated with fecal carriage of ESBL-PE.
The magnitude of ESBL-PE and MDR was high in the study area. Meropenem and imipenem were active against ESBL-PE. Therefore, strict infection control measure is needed in the study area to limit the infection and dissemination of ESBL-PE.
产超广谱β-内酰胺酶(ESBL-PE)的胃肠道定植率是医疗机构中感染和耐药克隆传播的主要危险因素。本研究旨在调查埃塞俄比亚阿姆哈拉州北绍阿德布雷伯汉综合专科医院住院患者中ESBL-PE的粪便携带情况及相关因素。
2020年11月至2021年3月,对383例住院患者进行了一项基于医院的横断面研究。无菌采集粪便样本或直肠拭子,在不同培养基上培养以分离[具体细菌名称未给出]。通过常规生化试验进行鉴定。使用头孢噻肟和头孢他啶筛选超广谱β-内酰胺酶(ESBL)的产生,并通过组合纸片法进行确认。使用社会科学统计软件包25版进行数据分析,P值≤0.05被认为具有统计学意义。
在383例住院患者中,共分离出347株[具体细菌名称未给出]。ESBL-PE的总体胃肠道定植率为47.3%(164/347)。主要的ESBL-PE是[具体细菌名称未给出]占54.9%(90/164)和[具体细菌名称未给出]占33.5%(55/164)。总体多重耐药率(MDR)为87.8%(305/347)。观察到对氨苄西林的耐药率最高(98.3%),其次是庆大霉素(80.7%)和四环素(73.3%)。ESBL-PE对美罗培南(90.2%)和亚胺培南(89.0%)高度敏感。过去3个月内使用抗生素的病史(p<0.001)、入住新生儿重症监护病房(p=0.023)和患有慢性病(p<0.001)与ESBL-PE的粪便携带独立相关。
研究区域内ESBL-PE和MDR的发生率较高。美罗培南和亚胺培南对ESBL-PE有活性。因此,研究区域需要采取严格的感染控制措施,以限制ESBL-PE的感染和传播。